(Q40359028)

English

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer

scientific article published on 10 May 2010

In more languages
default for all languages
No label defined

No description defined

Statements

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer (English)
S Gail Eckhardt
Scot Ebbinghaus
Peter J O'Dwyer
Michael S Gordon
William Novotny
Meredith A Goldwasser
Tanyifor M Tohnya
David S Mendelson

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit